tetano
Editor, Senior Moderator
Cureus
. 2022 Feb 27;14(2):e22669.
doi: 10.7759/cureus.22669. eCollection 2022 Feb.
Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature
Hamzeh M Alrawashdeh[SUP] 1 [/SUP], Omar Al-Habahbeh[SUP] 2 [/SUP], Abdallah Y Naser[SUP] 3 [/SUP], Hashem Abu Serhan[SUP] 4 [/SUP], Omar Hamdan[SUP] 5 [/SUP], Kanar Sweiss[SUP] 6 [/SUP], Yousef Aldalameh[SUP] 6 [/SUP]
Affiliations
Abstract
Lichen planus is an autoimmune inflammatory disease that can be associated with infections, drugs, and vaccines. Recently, it has been reported to occur following mRNA-based COVID-19 vaccines, particularly the Pfizer/BioNTech vaccine. We present the first reported case of lichen planus that developed after five days following the administration of the first dose of the Oxford-AstraZeneca vaccine in a 46-year-old healthy male. The skin eruption was purple, ill-defined, non-scaly, itchy, and distributed over his face, abdomen, back, and legs. The clinical appearance of the skin eruption and histopathology confirmed the diagnosis of lichen planus. The skin lesions were not responding well to topical steroid and oral antihistamine treatment. Thus, the patient was commenced on systemic hydroxychloroquine. The mechanism of lichen planus development following the administration of COVID-19 vaccines is unclear and needs more investigations and explanations. Healthcare providers should be aware of this possible adverse reaction following the administration of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. The histopathological features of lichen planus in our case are different from those found in the lichenoid drug eruption. This finding indicates different pathophysiology that needs further investigation.
Keywords: coronavirus; covid-19; lichen planus; oxford-astrazeneca vaccine; sars-cov-2.
. 2022 Feb 27;14(2):e22669.
doi: 10.7759/cureus.22669. eCollection 2022 Feb.
Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature
Hamzeh M Alrawashdeh[SUP] 1 [/SUP], Omar Al-Habahbeh[SUP] 2 [/SUP], Abdallah Y Naser[SUP] 3 [/SUP], Hashem Abu Serhan[SUP] 4 [/SUP], Omar Hamdan[SUP] 5 [/SUP], Kanar Sweiss[SUP] 6 [/SUP], Yousef Aldalameh[SUP] 6 [/SUP]
Affiliations
- PMID: 35386174
- PMCID: PMC8967128
- DOI: 10.7759/cureus.22669
Abstract
Lichen planus is an autoimmune inflammatory disease that can be associated with infections, drugs, and vaccines. Recently, it has been reported to occur following mRNA-based COVID-19 vaccines, particularly the Pfizer/BioNTech vaccine. We present the first reported case of lichen planus that developed after five days following the administration of the first dose of the Oxford-AstraZeneca vaccine in a 46-year-old healthy male. The skin eruption was purple, ill-defined, non-scaly, itchy, and distributed over his face, abdomen, back, and legs. The clinical appearance of the skin eruption and histopathology confirmed the diagnosis of lichen planus. The skin lesions were not responding well to topical steroid and oral antihistamine treatment. Thus, the patient was commenced on systemic hydroxychloroquine. The mechanism of lichen planus development following the administration of COVID-19 vaccines is unclear and needs more investigations and explanations. Healthcare providers should be aware of this possible adverse reaction following the administration of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. The histopathological features of lichen planus in our case are different from those found in the lichenoid drug eruption. This finding indicates different pathophysiology that needs further investigation.
Keywords: coronavirus; covid-19; lichen planus; oxford-astrazeneca vaccine; sars-cov-2.